Coronavirus Scientific Advisory Board (Turkey)

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors

Retrieved on: 
Friday, January 6, 2023

CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors.
  • "Blueprint Medicines' success to date is impressive and the company has a clear, exciting path to achieve its 2027 vision," said Dr. Tsai.
  • In addition, the company announced that George D. Demetri, M.D., FASCO, has retired from the Board of Directors and will be joining its Scientific Advisory Board.
  • Dr. Tsai joins the Board of Blueprint Medicines with more than 20 years of experience in bringing innovative therapies to market across geographies and therapeutic areas.

Karuna Launches the World's Largest Inner Child Collective of Multidisciplinary Teachers to Unleash Joy & Compassion Through Playful Micro-Journeys

Retrieved on: 
Thursday, January 5, 2023

ORLANDO, Fla., Jan. 5, 2023 /PRNewswire/ -- Karuna International, Inc. today announced the launch of the world's largest inner child collective of teachers, practitioners, thought-leaders, and learners.

Key Points: 
  • ORLANDO, Fla., Jan. 5, 2023 /PRNewswire/ -- Karuna International, Inc. today announced the launch of the world's largest inner child collective of teachers, practitioners, thought-leaders, and learners.
  • Karuna is on a mission to help people access the joy of their inner child by unleashing their boundless compassion for themselves and for the world.
  • To realize this mission, Karuna has organized experts from around the globe to curate evidence-based micro-journeys for healing the inner child.
  • Karuna today is building the world's largest inner child collective of teachers, thought-leaders, and learners.

Global Thought Leaders Continue to Join the VESTECK Advisory Team

Retrieved on: 
Thursday, January 5, 2023

WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.

Key Points: 
  • WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board.
  • The VESTECK "SUTURE-TIGHT"™ catheter secures endovascular aortic repair grafts (EVAR) to the aorta at the time of initial implant or during repair procedures.
  • VESTECK CEO, Joe Rafferty commented, "we are honored to have Professor Reijnen join our Scientific Advisory Board.
  • On the VESTECK Scientific Advisory Board, Professor Reijnen joins global thought leaders: Sean Lyden MD Cleveland Clinic, Daniel Clair MD Vanderbilt Univ., Prof. Andrew Holden Auckland Hosp NZ, William Gray MD Main Line Health, Dai Yamanouchi MD Univ.

Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases

Retrieved on: 
Wednesday, January 4, 2023

BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.

Key Points: 
  • BOSTON, Jan. 4, 2023 /PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board.
  • "Each of our SAB members brings unrivaled scientific expertise across key areas of neurodegenerative disease biology, preclinical development, and clinical testing that will be invaluable as we advance our first-in-class small-molecule drugs for Parkinson's disease, Alzheimer's disease, and ALS into clinical trials."
  • He has been recognized for this research and leadership contributions in the field of Alzheimer's disease through numerous awards.
  • Her laboratory specializes in the identification and treatment of disease targets in neurodegenerative conditions through translational modeling.

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Retrieved on: 
Wednesday, January 4, 2023

"I am pleased to announce Stacy's promotion to Co-CEO which is part of a broader strategic initiative to build out our leadership team and position BrainStorm for success," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "Stacy is a strong, collaborative leader who is passionate about transforming the lives of patients through innovation. Her track record in late-stage clinical development and commercial strategy means that she is exceptionally well qualified to guide BrainStorm as we prepare to enter our next phase as a company. I look forward to working with Stacy as we execute on our ultimate goals -- to make NurOwn available to patients and to create value as a commercial organization."  

Key Points: 
  • NEW YORK, Jan. 4, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer.
  • This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success.
  • Stacy Lindborg, Ph.D. joined BrainStorm in 2020 serving most recently as Executive Vice President and Chief Development Officer.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Retrieved on: 
Tuesday, January 3, 2023

Two esteemed nephrologists join ZyVersa's Renal Scientific Advisory Board, Drs.

Key Points: 
  • Two esteemed nephrologists join ZyVersa's Renal Scientific Advisory Board, Drs.
  • Cattran and Fervenza are joining our Scientific Advisory Board," stated Dr. Pablo Guzman, ZyVersa's Chief Medical Officer, and Chairman of the Renal Scientific Advisory Board.
  • "Their clinical and research expertise have earned them global distinction as key thought-leaders in the field of nephrology.
  • We look forward to their invaluable contributions that will help drive the timely success of our clinical development program for our cholesterol efflux mediator, VAR 200," continued Dr. Guzman.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer

Retrieved on: 
Monday, December 19, 2022

We accomplished this by filing 4 new patents applications in the areas of mRNA vaccines and CAR T-cell therapies.

Key Points: 
  • We accomplished this by filing 4 new patents applications in the areas of mRNA vaccines and CAR T-cell therapies.
  • In addition, we had 2 patents issued by the US patent office which protect our composition of matter around inhibiting and activating NR2F6 using small molecules.
  • While the Company has many exciting pipeline products, we need to focus our limited resources towards what we believe will provide patients and our shareholders the maximum benefit.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Dr. Karlene Cimprich, Ph.D., and Dr. Kornelia Polyak, M.D., Ph.D., to its Scientific Advisory Board. 

Key Points: 
  • Her work is relevant to IDEAYA's potential first-in-class pipeline programs in synthetic lethality DNA Damage Repair.
  • IDEAYA plans to clinically evaluate IDE161, its potential first-in-class inhibitor of poly (ADP-ribose) glycohydrolase (PARG), as monotherapy, including in BRCA1/2-mutant breast cancer patients.
  • Cimprich and Polyak as we continue to expand the breadth and depth of medical and scientific expertise on the IDEAYA Scientific Advisory Board.
  • "Our Scientific Advisory Board is integral to advancing our synthetic lethality programs.